Login to Your Account



Sanofi 'Selecta's Early Stage Immunotherapy in $900M Deal

By Marie Powers
Staff Writer

Thursday, November 29, 2012

Nanomedicine specialist Selecta Biosciences Inc., which has moved with rapid-fire speed over the past two years, landed a potential $900 million deal with Sanofi SA to discover targeted, antigen-specific immunotherapies for food allergies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription